ann summary from 23_01_2009 to present

Reference material

23/01/2009 Trading Halt
27/01/2009 Suspension from Official Quotation
30/01/2009 Appendix 4C - quarterly
3/02/2009 Stirling Products Market Update
3/02/2009 Reinstatement to Official Quotation
3/02/2009 Capital Raising and Board Restructure
9/02/2009 Initial Directors Interests_Appendices 3X
9/02/2009 Final Directors Interest Notice _ C London
9/02/2009 Final Directors Notice _S Patelakis
9/02/2009 Final Directors Interest Notice_ C Page
9/02/2009 Appendix 3B
9/02/2009 Stirling Products 708A(5)(e) Notice
9/02/2009 Stirling Appoints New Board
9/02/2009 Placement Advice
16/02/2009 Company Update
23/02/2009 Change of Director`s Interest Notice
23/02/2009 Placement - Second Tranche Completed
26/02/2009 Director Appointment
26/02/2009 Appendix 3B
26/02/2009 Stirling Products 708A(5)(e) Notice
27/02/2009 Half Yearly Accounts
27/02/2009 Appendix 4D
9/03/2009 Trading Halt
11/03/2009 Progress Report and Potential Joint Venture
25/03/2009 Progess Report
25/03/2009 Progress Report
31/03/2009 Presentation at 4th South African AIDS Conference
2/04/2009 Immunoxel Clinical Study Success Receives U.S. CRDF Award
14/04/2009 Agreement with and Contribution From NRC-IRAP
16/04/2009 Breakthrough in Extensively Drug-Resistant Tuberculosis
20/04/2009 Obesity Drug Candidate and Stirling Progress
23/04/2009 Shipment of First Immunoxel Order
29/04/2009 Swine Flu Prevention and Treatment Potential
29/04/2009 Capital Raising Advice
29/04/2009 Notice of General Meeting/Proxy Form
30/04/2009 Stirling Product Positioning and Potential
30/04/2009 Appendix 4C - quarterly
5/05/2009 Trading Halt
7/05/2009 General Meeting and Market Advice and Comment
7/05/2009 Major South African and African Joint Venture
14/05/2009 AIDS Patients in Trial Respond to Immunoxel
19/05/2009 Sale of Unmarketable Parcels of Shares
19/05/2009 Release of Supplementary Independent Expert`s Report
26/05/2009 Immunoxel Approved in South Africa
27/05/2009 International Union against TB and Lung Disease Presentation
28/05/2009 Managing Director`s Address to Shareholders
29/05/2009 Results of General Meeting
2/06/2009 "Influenza, TB and AIDS Products to be Prioritised "
4/06/2009 Progress Report and First Sales
5/06/2009 Appendix 3B
9/06/2009 Company Presentation - Melbourne
10/06/2009 Distribution and Product Sale Agreement - Mexico
12/06/2009 Appendix 3B
19/06/2009 Appendix 3B
22/06/2009 Product Sales Progress
24/06/2009 Trading Halt
26/06/2009 Appendix 3B
26/06/2009 Becoming a substantial holder
26/06/2009 Pharmaceutical Business Acquisition in Process
1/07/2009 Change of Director`s Interest Notice
1/07/2009 Change of Director`s Interest Notice
1/07/2009 Change of Director`s Interest Notice
2/07/2009 Appendix 3B
8/07/2009 Change in substantial holding
13/07/2009 Appendix 3B
17/07/2009 Stirling Withdraws From Pharmaceutical Business Acquisition
20/07/2009 High Cure Rate in TB and Aids Co-infected Patients
21/07/2009 Stirling Announces Appointments and Operational Structure
28/07/2009 Change in substantial holding
28/07/2009 Stirling to Host Conference in Mexico
29/07/2009 Appendix 3B
31/07/2009 Progress and Quarterly Report
31/07/2009 Appendix 4C - quarterly
3/08/2009 USA Market Launch
5/08/2009 LOI Entered Into For Brazil
10/08/2009 Appendix 3B
11/08/2009 Change of Share Registry- Unmarketable Parcel Sale
20/08/2009 Stirling Secures Sydney HQ Freehold
27/08/2009 Trading Halt
28/08/2009 New Drug Delivery Platform Acquisition
31/08/2009 Appendix 4E - Preliminary Final Report
31/08/2009 Appendix 3B
9/09/2009 Company Updates on Acivities
11/09/2009 Appendix 3B
11/09/2009 Director Appointment/Resignation
18/09/2009 Initial Director`s Interest Notice
18/09/2009 Final Director`s Interest Notice
22/09/2009 Appendix 3B
29/09/2009 Share Purchase Plan
1/10/2009 Full Year Statutory Accounts
7/10/2009 Share Purchase Plan
7/10/2009 Cleansing Notice For Share Purchase Plan (SPP)
14/10/2009 Stirling North American Launch Advice
15/10/2009 Appointment of Specialist Network Marketing Counsel in USA
20/10/2009 South Africa Grants Provale Patent
21/10/2009 PRESENTATION TO INDIA AUSTRALIA INVESTMENT FORUM
21/10/2009 North American Launch Update
22/10/2009 COMMERCIAL OPPORTUNITY OF HDA DRUG DELIVERY PLATFORM
22/10/2009 DRUG DELIVERY PLATFORM ACQUISITION AGREEMENT FINALISED
23/10/2009 Notice of Annual General Meeting/Proxy Form
27/10/2009 SPP SUPPORT RAISES $1.6M
30/10/2009 Appendix 4C - quarterly
4/11/2009 Appendix 3B
5/11/2009 Progress Report
16/11/2009 Stirling Reports Increase of Sales in Mongolia
18/11/2009 TB and HIV Clinical Trial and Marketing Contract for Nigeria
26/11/2009 Managing Director`s Address to Shareholders
26/11/2009 Placement $1.5 Million
27/11/2009 Results of Meeting
2/12/2009 Clarification of Pharma Plant Acquisition
2/12/2009 Acquisition of Licensed Pharmaceutical Plant
3/12/2009 Stirling to Present at INVEST IN AUSTRALA
4/12/2009 Stirling Products Presentation INVEST IN AUSTRALIA
10/12/2009 Finance News Network Interview With Managing Director
23/12/2009 Stirling Products To Launch Generc Pharmacy Range
30/12/2009 "Appointment of Product, Brand and Marketing Specialist "
11/01/2010 Small Trial Result in TB and HIV Patients
14/01/2010 Funding from Major US Granting Agency Initiated
22/01/2010 Cleansing Statement
22/01/2010 Appendix 3b
22/01/2010 Placement and Share Issues
28/01/2010 Immunoxel to be Tested in Flu- Comparison Against Flu Drugs
28/01/2010 Appointment of Sales and Marketing Director and COO
29/01/2010 Appendix 4C - quarterly
2/02/2010 Response to ASX Aware Letter Query
12/02/2010 Progress Report
24/02/2010 Ethics Approval Received for Flu Trial
26/02/2010 Half Yearly Financial Report
26/02/2010 Placement $1.4 Millon
1/03/2010 Trading Halt
1/03/2010 Appendix 4D Half Year Report 31 dec 2009
3/03/2010 Appendix 3B
3/03/2010 Pharmaceutical Plant Acquisition
4/03/2010 UK Diretor Appointed
9/03/2010 Finance News Network Video Interview with Managing Director
15/03/2010 Stirling Health Launch
18/03/2010 Presentation
24/03/2010 Presentation
30/03/2010 Director Appointment/Resignation
31/03/2010 HIV TB and Flu Trials in Progress
1/04/2010 Response to ASX Query re Appendix 3X
8/04/2010 Reclassification of 30th March 2010 Announcement
8/04/2010 Appendix 3B
9/04/2010 Appoinments
29/04/2010 Inhalation Drug Delivery Platform Update
30/04/2010 Appendix 4C - quarterly
3/05/2010 Progress Report 3 May 2010
4/05/2010 Change of Director`s Interest Notice
5/05/2010 WHO and U.S. NIH Immunoxel Clinical Trial Listings
6/05/2010 Change of Director`s Interest Notice
7/05/2010 Request for Trading Halt
7/05/2010 Trading Halt
11/05/2010 Unique New Product Range and Launch
13/05/2010 Key Consulting Appointment to HDA Device Commercialisation
17/05/2010 New Product Range Honey Format Wins Award at SIAL in Paris
18/05/2010 Broker Presentation
21/05/2010 Trading Halt
25/05/2010 Australian Integrated Medicine Association Sponsorship
25/05/2010 Clarification of Previous Annoucement
25/05/2010 Major Partnership With Kidney Health Australia
7/06/2010 Appointment Formalisation and Pharma Expo 2010
15/06/2010 Drug Delivery Platform Strategy Presentation
15/06/2010 Drug Delivery Platform Strategy
25/06/2010 Quoted Options Expiring 30 June 2010
30/06/2010 Managing Director`s Year End Review
5/07/2010 HIV Treatment Benefits of Immunoxel Supported by Study in US
8/07/2010 FDA Guidance Use of Antibiotics in Animal Growth Promotion
14/07/2010 Quoted Options Notice Expiring 30 June 2010
14/07/2010 Appendix 3B
14/07/2010 Update on Canadian Pharmaceutical Plant Licensing
15/07/2010 Patent Issue for Obesity Drug Australia
22/07/2010 Investment inTeleMedCare Holdings Pty Ltd
23/07/2010 Funding Facility Clarification
28/07/2010 Finance News Network Video Interview with Managing Director
30/07/2010 Appendix 4C - Quarterly
30/07/2010 Trading Halt
3/08/2010 TeleMedCare Acquisition
5/08/2010 Response to ASX Appendix 4C Query
10/08/2010 Funding for $3.9million
11/08/2010 TeleMedCare Transaction Finalises and Industry Meetings
13/08/2010 TeleMedCare Pharmacy Pilot
17/08/2010 TeleMedCare UK Awarded Governent Sales Channel Partnering
19/08/2010 Executive Appointment and Production Progress
24/08/2010 TeleMedCare Devices in Boots UK Pharmacy Pilot
25/08/2010 New Horizons for TeleMedCare UK
26/08/2010 Appendix 3B
26/08/2010 TeleMedCare Monitor Demonstrated on ABC
31/08/2010 Preliminary Final Report
2/09/2010 Appendix 3B
10/09/2010 Advice regarding Property Sales
14/09/2010 Trading Halt
16/09/2010 Pathology Business Acquisition
20/09/2010 ImmunoXel Study Proposed with US Research Institute
22/09/2010 Stirling Pharma subsidiary presentation
27/09/2010 Appendix 3B
27/09/2010 "Progress, Strategy and Focus Report "
28/09/2010 Finance News Network Interview Stirling Executives
30/09/2010 Full Year Statutory Accounts
15/10/2010 Stirling Pharma Gains Health Canada Site Licence
25/10/2010 TeleMedCare and Funding
26/10/2010 Safer Drug Regime Broker Presentation
28/10/2010 CFO Appointment
28/10/2010 Appendix 3B
29/10/2010 Appendix 4C - quarterly
1/11/2010 Notice of Annual General Meeting/Proxy Form
19/11/2010 Trading Halt
23/11/2010 Response to ASX Query re Appendix 4C
23/11/2010 Termination of Agreement and Funding
25/11/2010 Product Demonstrations to Shareholders and Media at AGM
29/11/2010 Managing Director`s Shareholders` Address
29/11/2010 Pharma Plant Licensing
30/11/2010 Results of Meeting
10/12/2010 Trading Halt
14/12/2010 Funding of up to $6Million
16/12/2010 Appendix 3B
20/12/2010 Trading Policy
22/12/2010 Stirling Update
4/01/2011 Appendix 3B
5/01/2011 Stirling Wins 3M Contract for Australian Pharmacies
10/01/2011 Pharmaceutical Manufacturing License Issue Stirling Pharma
11/01/2011 Response to ASX Query
13/01/2011 Successful TeleMedCare Trial
17/01/2011 TeleMedCare FDA Filing
19/01/2011 Change of Director`s Interest Notice
20/01/2011 Change of Director`s Interest Notice
25/01/2011 Appendix 3B
31/01/2011 Appendix 4C - quarterly
31/01/2011 Microsoft features TeleMedCare in Whitepaper
7/02/2011 Trading Halt
8/02/2011 Funding and Corporate Presentation